---
figid: PMC11315656__ijmm-54-04-05408-g04
pmcid: PMC11315656
image_filename: PMC11315656__ijmm-54-04-05408-g04.jpg
figure_link: /pmc/articles/PMC11315656/figure/F5/
number: Figure 5
figure_title: Immune infiltration and GSEA of NCAPD2 in liver cancer.
caption: Immune infiltration and GSEA of NCAPD2 in liver cancer. (A) Immune infiltration
  analyses of the ESTIMATE algorithm, including stromal score, immune score and ESTIMATE
  score in liver cancer with high and low NCAPD2 expression. (B) Immune cell abundance
  of high or low NCAPD2 expression groups in liver cancer. (C) GSEA for the NCAPD2-related
  signaling pathways in liver cancer. Single-cell sequencing analysis of NCAPD2 expression
  in liver cancer derived from (D) GSE140228 and (E) GSE112271 datasets. **P<0.01,
  ***P<0.001. ESTIMATE, Estimation of STromal and Immune cells in MAlignant Tumor
  tissues using Expression data; GSEA, gene-set enrichment analysis; mTOR, mammalian
  target of rapamycin; NCAPD2, non-SMC condensin I complex subunit D2; PI3K, phosphatidylinositol
  3-kinase
article_title: NCAPD2 augments the tumorigenesis and progression of human liver cancer
  via the PI3K-Akt-mTOR signaling pathway
citation: Jiang-Xue Gu, et al. Int J Mol Med. 2024 Oct;54(4).
year: '2024'
pub_date: 2024-10-
epub_date: 2024-7-31
doi: 10.3892/ijmm.2024.5408
journal_title: International Journal of Molecular Medicine
journa_nlm_ta: Int J Mol Med
publisher_name: D.A. Spandidos
keywords:
- non-SMC condensin I complex subunit D2
- liver cancer
- phosphatidylinositol 3-kinase-Akt-mammalian target of rapamycin
- c-Myc
- epithelial-mesenchymal transition
- tumor survival and progression
---
